Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Deal Watch: Zymeworks Adds Daiichi To List Of Partners In I-O Cross Collaboration

Executive Summary

Amgen gets into RNAi for cardiovascular indications with Arrowhead deal. Lilly and J&J out-license preclinical candidates, for epilepsy and cancer respectively, to smaller firms Cerecor and Tracon.


Related Content

Deal Watch: Novartis Opts In On Lipoprotein A Candidate From Akcea
Deal Watch: Allogene Gets Pfizer's Off-The-Shelf CAR-T Program, $300m Series A Backing
R&D Head Sean Harper On Amgen's Long-Term Investment View
J&J Deal Helps Zymeworks Continue Transformational Year
Surprise Boehringer Decision Turns Hanmi Investors’ Hopes To Despair
Maruho Broadens Derma Horizons Through Dual Licensing Deals
Hanmi Does It Again - RAF Inhibitor Goes To Genentech In $910m Deal
Boehringer Gets Option To Buy ViraTherapeutics And Cancer Virus Therapy
Boehringer Increasingly Looking Outside For Oncology Growth
Zymeworks, GSK Sign Antibody Deal For Up To $440m


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts